The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...
We conducted a phase 1b–2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A ...
Roche RHHBY announced that it will acquire clinical-stage biopharmaceutical company Poseida Therapeutics, Inc. PSTX for $9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback